Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.

Just a month after it gave the new Alzheimer's drug aducanumab (Aduhelm) the green light, the FDA decided to change the label.

No aspect of life was immune from the COVID-19 pandemic — not even a mega, international event that comes around only once every four years.

The American Psychological Association says 42 percent of Americans reported that they gained an average of 29 pounds during the pandemic, far above the pound or two Americans gain in an average year.

As particles from the sun and high-energy cosmic radiation stream constantly into their bodies, astronauts are always in danger. Radiation can cause serious health problems if it is not controlled.

The proposed guideline would give all astronauts the same radiation limit, regardless of age and sex.

A blue-ribbon panel has endorsed NASA’s plans to revise its standard for exposing astronauts to radiation in a way that would allow women to spend more time in space.

A blue-ribbon panel has endorsed NASA’s plans to revise its standard for exposing astronauts to radiation in a way that would allow women to spend more time in space.

The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen.

Now that the FDA has approved Biogen's aducanumab (Aduhelm), the controversial new drug for Alzheimer's disease, what does this mean?

In a watershed moment for the field, the U.S. Food and Drug Administration yesterday approved the first Alzheimer’s treatment that tackles the underlying disease pathology.

The first drug to treat Alzheimer’s disease in 18 years, which was extensively researched at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, has won approval from the Food and Drug Administration.